B2M and neoplasm: Tumor-upregulated proteins significantly converged on pathways including glycolysis/gluconeogenesis (e.g., HK2, PFKP, ALDOA, PGK1), interferon gamma mediated signaling (e.g., OAS1, FCGR1A, TRIM5, GBP1), immune response (e.g., IFITM3, CD40, HLA-DMA), antigen processing and presentation (e.g., CANX, PSME2, B2M), ECM-receptor interaction (e.g., COL2A1, VWF, LAMA4), NF-κB signaling (e.g., BCL2, LCK, LYN, NFKB2), HIF-1 signaling (e.g., EGFR, FLT1, HK2, PDK1, PIK3CD), and PI3K-AKT signaling (e.g., GYS2, ITGA5, PDK1, PIK3CD, TCR2).